The efficacy and peripheral blood predictors in recurrent platinum-resistant ovarian cancer patients treated with immune checkpoint inhibitors

作者：Baoyue Pan, Xiaojing Zheng, Yongwen Huang, Wei Wei, Shije Xu, Siyu Chen, Jiaxin Yin, Yu Zhang, Jundong Li, Min Zheng · 发表于：Journal of Ovarian Research · 年份：2025 · DOI：10.1186/s13048-025-01755-7 · 被引用次数：2 · 研究领域：Ovarian cancer diagnosis and treatment、Cancer Immunotherapy and Biomarkers、PARP inhibition in cancer therapy

INTRODUCTION: The prognostic factors associated with recurrent platinum-resistant ovarian cancer treated with immune checkpoint inhibitor (ICI) therapy need to be identified. METHODS: We retrospectively analyzed the efficacy of ICI therapy in patients with recurrent platinum-resistant ovarian cancer at our center. The number of CD8 + T cells and the expression of PD-L1 were assessed using immunohistochemical assays. A multi-analyte flow assay was used to detect the concentrations of 13 inflammatory cytokines. Both univariate and multivariate models were constructed using pretreatment clinical variables and cytokines. RESULTS: We included 71 patients with recurrent platinum-resistant ovarian cancer treated with at least two cycles of anti-programmed cell death 1 (PD-1); the objective response rate was 36.62%, and the disease control rate was 78.87%. Elevated levels of interferon-alpha 2 (IFN-α2), IL-1β, and IL-12p70 in serum were associated with improved overall survival. Higher levels of monocyte chemoattractant protein 1 (MCP-1) correlated with longer overall survival and progression free survival. According to the results of the multivariate analysis, a high level of C-reactive protein (CRP) (> 10) independently predicted overall survival. Age, low-density lipoprotein cholesterol (LDL-C), tumor necrosis factor-alpha (TNF-α), and MCP-1 were independently associated with progression-free survival. Chemotherapy containing platinum after immunotherapy progression achieved a par...